Business ❯Pharmaceutical Industry

Market Competition

Drug Safety Infectious Diseases Regulations Epidemiology Pharmaceutical Pricing Drug Manufacturing Patient Care Intellectual Property Disease Prevention Drug Development

Novo Nordisk’s CagriSema Delivers 20.4% Weight Loss, Shares Drop

Investors have expressed skepticism over side effects alongside concerns about its delayed market debut following full trial results.

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

Trump's Executive Order Enacts Global Benchmark for U.S. Drug Prices

Novo Nordisk Revises 2025 Outlook as FDA Crackdown and Competition Reshape Wegovy Market

Eli Lilly Expands Legal Fight Against Compounded GLP-1 Drugs

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Pfizer Halts Development of Oral Weight-Loss Pill After Liver Injury

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Taxpayer-Funded Weight-Loss Drugs Face Scrutiny Over High Prices

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

FDA Declares Semaglutide Shortage Over, Impacting Compounded Drug Market